Groupe Francophone Des Myelodysplasies

This study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose myelodysplastic syndrome or acute myeloid leukemia has returned after a stem cell transplant. The goal is to find the safest dose and see if this approach can improve …

This study is for people with a high-risk blood disorder called myelodysplastic syndromes (MDS) who have not had treatment before and cannot have a stem cell transplant. Researchers are testing two oral medications, Onureg and Venetoclax, to find the safest and most effective dos…

This study is a registry that tracks 400 adults aged 70 or younger with a specific, less aggressive form of acute promyelocytic leukemia (APL). It compares two standard first-line treatments—ATRA plus chemotherapy versus ATRA plus arsenic trioxide—to see which is more effective a…